Welcome to our dedicated page for Kiora Pharma SEC filings (Ticker: KPHMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kiora Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kiora Pharma's regulatory disclosures and financial reporting.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.
KIORA PHARMACEUTICALS, INC. filing: Alyeska Investment Group and related filers report 394,668 shares beneficially owned, representing 9.99% of Common Stock as of March 31, 2026. The position equals the maximum exercisable under a beneficial ownership limitation tied to warrants.
The filing states the Reporting Persons hold warrants exercisable for 596,854 shares, but the 9.99% limitation permits exercise of only 394,668 shares based on 3,950,628 shares outstanding per the Form 10-K dated March 25, 2026. Voting and investment control is exercised by Alyeska Investment Group, L.P.; Anand Parekh is named but disclaims beneficial ownership.
KIORA PHARMACEUTICALS, INC. filing: Alyeska Investment Group and related filers report 394,668 shares beneficially owned, representing 9.99% of Common Stock as of March 31, 2026. The position equals the maximum exercisable under a beneficial ownership limitation tied to warrants.
The filing states the Reporting Persons hold warrants exercisable for 596,854 shares, but the 9.99% limitation permits exercise of only 394,668 shares based on 3,950,628 shares outstanding per the Form 10-K dated March 25, 2026. Voting and investment control is exercised by Alyeska Investment Group, L.P.; Anand Parekh is named but disclaims beneficial ownership.
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related share disposition. On April 1, 2026, he transferred 1,906 shares of Common Stock at $1.95 per share to cover taxes by delivering shares instead of cash. After this tax-withholding disposition, he directly holds 60,692 shares of Kiora common stock. This was not an open-market sale or purchase but a routine mechanism tied to equity compensation.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.
Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA will resign effective April 17, 2026 to pursue another opportunity. The company stated his departure is not due to any disagreement over operations, policies, or practices and has begun a search for his successor.
Kiora emphasized continued progress in its retinal disease pipeline. In the ABACUS-2 Phase 2 trial of KIO-301, a planned safety review allowed enrollment of remaining patients in the 50µg dose cohort and cleared initiation of the 100µg cohort. In the KLARITY Phase 2 trial of KIO-104, all planned safety checkpoints have been cleared and patient enrollment is ongoing.